CATIE news story
— Long-acting HIV treatment with cabotegravir + rilpivirine is an option for some people.
— International guidelines do not recommend its use during pregnancy due to efficacy concerns.
— Researchers found promising results in pregnancy when oral therapy alone was not an option.
Scientists at the Ottawa Hospital noted that the use of Cabenuva (cabotegravir + rilpivirine) could be helpful during pregnancy in people with HIV. For instance, pregnancy-related nausea can make it difficult to take medicines orally, which would make adherence challenging. They described their experience with the first seven women with HIV who received Cabenuva during pregnancy at their clinic.
Read the full news story here.